News & Publications
Immodulon appoints Professor Bams Abila as Chief Medical Officer
Professor Abila brings extensive experience in clinical drug development. Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect. Professor Abila has...
read moreBiodesix and Immodulon Announce Research Collaboration for Pancreatic Cancer Treatment
Biomarker Research for IMM-101 Utilizing the Biodesix Diagnostic Cortex™ Platform BOULDER, Colo. and UXBRIDGE, UK, July 25, 2019 – Biodesix Inc. and Immodulon Therapeutics Limited, the immune-oncology company, today announced that they have entered into a biomarker...
read moremyTomorrows and Immodulon to develop Expanded Access Programme
Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration...
read moreImmodulon appoints Dr Michael Bowles as Medical Director
Immodulon, the immuno-oncology company, today announces the appointment of Dr Michael Bowles, as Medical Director, with immediate effect. Dr Ruslan Croitoru has chosen to step down as Chief Medical Officer to pursue other interests. A search for a new CMO is underway....
read moreImmodulon appoints Dr Thomas Kleen as Chief Scientific Officer
Dr Kleen brings extensive experience in immunology and immune monitoring to help further advance the company’s lead, novel immuno-oncology product, IMM-101 Uxbridge, UK, 23 May 2019 – Immodulon, the immuno-oncology company, today announces the appointment of Thomas O....
read morePoster presentation of final IMAGE 1 data at SITC
Appointment of Ruslan Croitoru – Chief Medical Officer
Immodulon, the immuno-oncology company, is pleased to announce that Ruslan Croitoru (MD MSc (Oxon) MFPM) will be joining the Immodulon Core Management Team as the Chief Medical Officer. Ruslan is a cardiologist. He gained his medical degree in Moldova, where he...
read moreAppointment of Maikel Dijkstal – CMC Programme Manager
Immodulon, the immuno-oncology company, is pleased to announce that Maikel Dijkstal will be joining the Immodulon Core Management Team as CMC Programme Manager with immediate effect. Based in The Netherlands, Maikel has spent much of his working career in...
read moreCommencement of IMM-101 Phase II clinical trial in Melanoma
Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26...
read more